Business context and reporting period
This is Organovo Holdings, Inc.’s Form 10-K for the fiscal year ended March 31, 2018, filed May 31, 2018. The request metadata names “Vivosim Labs, INC.” and describes 2017 Q4; those do not match the registrant and reporting period shown in the filing. The fourth-quarter figures below are for the quarter ended March 31, 2018.
Organovo develops 3D-bioprinted human tissues for drug research and therapeutic applications, and sells specialized human cells through its Samsara Sciences subsidiary. Its lead therapeutic program targets Alpha-1-antitrypsin deficiency (A1AT); the FDA granted orphan drug designation in December 2017. The company targets an IND filing in calendar 2020. Commercial revenue is principally from products and services, collaborations and licenses, and grants.
Financial performance and liquidity
| Metric | FY ended Mar. 31, 2018 | FY ended Mar. 31, 2017 |
|---|---|---|
| Revenue | $4.603 million | $4.230 million |
| Products and services revenue | $3.627 million | $3.167 million |
| Collaborations and licenses | $0.422 million | $1.022 million |
| Grant revenue | $0.554 million | $0.041 million |
| Cost of revenue | $1.030 million | $0.956 million |
| Operating expenses | $39.874 million | $42.805 million |
| Operating loss | $(35.271) million | $(38.575) million |
| Net loss | $(34.803) million | $(38.447) million |
| Net loss per share, basic and diluted | $(0.32) | $(0.39) |
| Cash used in operating activities | $(28.857) million | $(29.185) million |
FY2018 product-and-service gross profit was approximately $2.597 million, or about 72% of that revenue. This is not a company-wide operating margin: total costs and expenses substantially exceeded revenue.
For the fourth quarter of FY2018, revenue was $1.105 million, net loss was $7.449 million, and basic and diluted loss per share was $0.07. The comparable FY2017 quarter reported revenue of $0.812 million and net loss of $10.657 million.
At March 31, 2018, cash and cash equivalents were $43.726 million; current assets were $46.760 million and current liabilities $4.658 million, yielding working capital of $42.102 million. Total assets were $49.827 million, total liabilities $5.241 million, and stockholders’ equity $44.586 million. The filing reports no material outstanding debt balance; liabilities chiefly included accrued expenses, deferred revenue, and deferred rent. Operating lease obligations totaled $4.030 million.
Cash declined $19.025 million during FY2018. Financing activities provided $10.113 million, including approximately $9.2 million of net proceeds from at-the-market stock sales. Management said existing cash and its operating plan were sufficient for at least the next 12 months, but that further capital would be needed for longer-term development and operations. The company reported cumulative net losses of $234.1 million.
Material changes versus the prior comparable year
- Revenue increased 9%, or $0.373 million. Product and service revenue rose $0.460 million and grants rose $0.513 million, partly offset by a $0.600 million decline in collaboration and license revenue as projects concluded.
- Operating loss narrowed by $3.304 million and net loss by $3.644 million, alongside lower R&D and selling, general and administrative expenses.
- R&D expense fell 8% to $17.956 million; SG&A fell 6% to $20.888 million. Management cited reduced staffing, lower legal and patent costs, and tighter project prioritization.
- Operating cash use improved by $0.328 million, but cash and cash equivalents fell from $62.751 million to $43.726 million, principally reflecting the operating cash burn and lower financing proceeds than in FY2017.
- Weighted-average shares outstanding rose to 107.2 million from 97.8 million. The company sold 5.307 million shares through ATM offerings during FY2018.
Outlook, risks and unusual items
- Management’s stated priorities include confirmatory animal studies and a pre-IND path for A1AT, advancing a possible second therapeutic indication, expanding NASH disease-modeling collaborations, and growing Samsara cell-product revenue. These are objectives, not assured results; the filing provides no conventional revenue or earnings guidance.
- Preclinical results included reported liver-tissue engraftment and sustained function through 125 days in diseased mice, with approximately 75% reduction in disease hallmarks near the implant versus untreated animals. These are animal-study findings, not evidence of demonstrated human efficacy.
- Key risks include sustained operating losses, uncertain customer adoption and collaboration revenue, the need for additional financing and potential shareholder dilution, early-stage therapeutic development, lengthy and uncertain FDA review, competition, and reliance on reliable supplies of human cells. The company also cited risks from its single San Diego laboratory location and potential disruption to operations.
- After year-end, on April 17, 2018, the company announced a restructuring affecting approximately 13 positions, or 15% of its workforce. It expected a roughly $0.4 million charge, mainly severance and benefits, in FY2019’s first quarter.
- The independent auditor issued an unqualified opinion on the financial statements and internal controls; management and the auditor reported effective internal control over financial reporting as of March 31, 2018. No material legal proceedings were reported.
Important facts for investors to verify
- Confirm the intended issuer and period: this filing is for Organovo Holdings, Inc., FY2018 ended March 31, 2018, not a 2017 Q4 filing for Vivosim Labs.
- Track cash burn against management’s stated minimum 12-month funding horizon, and whether additional financing or partnerships are secured.
- Monitor future revenue composition and repeatability, particularly product and service growth versus declining collaboration revenue and grant-dependent revenue.
- Assess progress toward the A1AT IND target, required preclinical validation, and any further FDA designations; do not equate animal findings with clinical benefit.
- Review potential dilution: the filing describes a $50 million ATM program and additional shelf capacity, alongside equity awards and a rising share count.
- Check the costs and operational effects of the post-year-end workforce restructuring and the company’s ability to maintain cell supply and laboratory operations.